Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 11

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 11
---
per is not a candidate or is unable to serve as a director at the time of the election (which is not currently expected), for any nominee who is designated by our board of directors to fill the vacancy. Ms. Kunz, Mr. Socks and Dr. Topper are each currently a member of our board of directors. In connection with this year’s annual meeting, and in light of the addition of Mr. Schroeder in April 2025 as an independent director, and Mr. Socks’ ongoing commitments, the board of directors has not re-nominated Mr. Socks. Mr. Socks will continue to serve as a director until his term expires at the annual meeting. Our board of directors has elected to reduce the size of the board from nine to eight directors, effective as of the date of the annual meeting. We thank Mr. Socks for his service to the company as a co-founder, executive, strategic advisor and as a member of our board of directors for many years. All of our directors bring to the board of directors significant leadership experience derived from their professional experience and service as executives or board members of other corporations and/or private equity and venture capital firms. The process undertaken by the nominating and corporate governance committee in recommending qualified director candidates is described below under “Director Nomination Process.” Certain individual qualifications and skills of our directors that contribute to the board of directors’ effectiveness as a whole are described in the following paragraphs. Information Regarding Directors The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for director: Members of the Board with a Term Expiring at the 2025 Annual Meeting of Stockholders and Nominees for Election to the Board of Directors For a Three-Year Term Expiring at the 2028 Annual Meeting of Stockholders (Class III)

| Name                      |     | Age |     | Present Position with Phathom Pharmaceuticals, Inc. |
| Heidi Kunz                |     |  70 |     | Director                                            |
| David Socks (1)           |     |  50 |     | Director                                            |
| James Topper, M.D., Ph.D. |     |  63 |     | Director                                            |

(1) Mr. Socks will not stand for re-election at the annual meeting. Heidi Kunz has served as a member of our board of directors since September 2019. Ms. Kunz served as Executive Vice President and Chief Financial Officer of Blue Shield of California from September 200